INVESTOR MATERIALS

Special Proxy Statement

Special Proxy Statement/Circular

View an enhanced version of our Special Proxy Statement/Circular.

Request Paper Materials

You may request paper materials of the above annual materials online, by email or by calling 866-648-8133.

VOTING

Your vote is Important!

Please be sure to vote your shares online now or vote by phone by dialing 866-834-5856.

Date & Time

  • May 29, 2024
  • 10:00 AM Eastern Time

Virtual Meeting

  • You must register to be eligible to participate in the meeting.

Special Meeting

INFORMATION

ABOUT US


Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.